<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04386499</url>
  </required_header>
  <id_info>
    <org_study_id>SR001</org_study_id>
    <nct_id>NCT04386499</nct_id>
  </id_info>
  <brief_title>Biological Effects of Treatment With Resveratrol in ART Patients</brief_title>
  <official_title>Effects of Treatment With Resveratrol on Oocyte and Embryo Quality in Patients Undergoing Assisted Reproductive Techniques( ART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of a new nutraceutical formulation containing resveratrol (trademark
      GENANTE) on gamete quality in order to improve the reproductive process during ART.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the effect of a new nutraceutical formulation
      containing resveratrol (trademark Genante) on gamete quality in order to improve the
      reproductive protocols during Assisted reproductive technology (ART) protocols.

      The study is a randomized, single blind, parallel, comparative, experimental study during the
      pre-treatment before in vitro fertilization-embryo transfer (IVF-ET). A total number of 100
      patients will be enrolled: 50 patients with a pretreatment control group (control group) and
      50 patients with experimental pretreatment study group (resveratrol group). Patients will be
      assigned to groups during the recruitment phase in a randomized manner. In the control group,
      the treatment will consist of taking 400 microg once a day of folic acid commonly suggested
      as part of clinical practice, while in the Resveratrol Group, patients will receive one
      tablet twice a day (two tablets/day) of Genante. It is specified that the pretreatment with
      Genante includes folic acid in accordance with the clinical practice, 400 total microg per
      day. Both treatments will last for 3 months before the IVF procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Actual">May 5, 2020</completion_date>
  <primary_completion_date type="Actual">March 11, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parallel, single blind, grouped randomised, interventional clinical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>follicles</measure>
    <time_frame>6 months</time_frame>
    <description>Number of follicles &gt;16 mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oocytes</measure>
    <time_frame>6 months</time_frame>
    <description>number of recovered oocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MII oocytes</measure>
    <time_frame>6 months</time_frame>
    <description>percentage of metaphase II oocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fertilization</measure>
    <time_frame>6 months</time_frame>
    <description>fertilization rates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>embryos</measure>
    <time_frame>6 months</time_frame>
    <description>number of embryos</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blastocysts</measure>
    <time_frame>6 months</time_frame>
    <description>number of blastocysts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gonadotropins days</measure>
    <time_frame>6 months</time_frame>
    <description>duration of ovarian stimulation (days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gonadotropins IU</measure>
    <time_frame>6 months</time_frame>
    <description>dosage of gonadotropins (total IU during ovarian stimulation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>embryos number</measure>
    <time_frame>18 months</time_frame>
    <description>number of embryos per transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation</measure>
    <time_frame>18 months</time_frame>
    <description>Implantation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pregnancy</measure>
    <time_frame>18 months</time_frame>
    <description>clinical pregnancy rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>live birth</measure>
    <time_frame>18 months</time_frame>
    <description>live birth rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage</measure>
    <time_frame>18 months</time_frame>
    <description>miscarriage rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A nutraceutical formulation (trade mark Genante) composed of resveratrol, REVIFAST, folic acid, Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Folic Acid 400 ug</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6</description>
    <arm_group_label>Resveratrol</arm_group_label>
    <other_name>Genante (S&amp;R Farmaceutici S.p.A, Italy)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic acid</intervention_name>
    <description>400 mcg of folic acid</description>
    <arm_group_label>Folic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a diagnosis of infertility

          -  BMI between 18 and 30 kg/m2,

          -  regular uterine cavity

          -  normal thyroid function

          -  normal blood parameters

        Exclusion Criteria:

          -  primary or secondary ovarian failure

          -  patients who adhered to Bologna Criteria (at least two of the following: advanced
             maternal age &gt;40, less than 3 oocytes recovered in previous attempts, abnormal ovarian
             reserve test)

          -  presence of ovaries inaccessible to the oocyte pick-up,

          -  persistent ovarian cysts &gt; 20 mm,

          -  presence of sactosalpinx

          -  heterologous fertilization, significant systemic disease or other situations
             unsuitable for ovarian stimulation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Gerli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Of Perugia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Perugia, Piazza Menghini 1, S. Andrea delle Fratte.</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Sandro Gerli</investigator_full_name>
    <investigator_title>Associate Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

